

1 *The International Journal of Lower Extremity Wounds*

2

3 **Evolution of Wifi: Expansion of Wifi Notation After Intervention**

4

5 Virginie Blanchette^{1,2}

6 Malindu E Fernando^{1,3,4}

7 Laura Shin¹

8 Vincent L Rowe¹

9 Kenneth R Ziegler¹

10 David G Armstrong¹

11

12 ¹ Southwestern Academic Limb Salvage Alliance (SALSA), Department of Surgery, Keck

13 School of Medicine of University of Southern California, Los Angeles, CA, USA

14 ² Department of Human Kinetics and Podiatric Medicine, Université du Québec à Trois-Rivières,

15 Trois-Rivières, Québec, Canada

16 ³ Ulcer and wound Healing consortium (UHEAL), Queensland Research Centre for Peripheral

17 Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville,

18 Queensland, Australia

19 ⁴ Faculty of Health and Medicine, School of Health Sciences, University of Newcastle, Australia

20

21 **Corresponding author:** Virginie Blanchette

22 Phone: 1-819-690-6338

23 Email: Virginie.Blanchette@uqtr.ca

24 **Keywords**

25 Diabetes, Lower Extremity, Foot Diseases, Orthopedic Procedures, Reoperation, Infection

26

27 **Declarations**

28 *Ethics approval and consent to participate:* Not applicable

29

30 *Consent for publication:* Not applicable

31

32 *Availability of data and materials:* Not applicable

33

34 *Conflicts of interest:* The authors have no conflict of interest for the research, authorship, and/or
35 related publication to this article.

36

37 *Funding:* None

38

39 *Acknowledgements:* None

40

41

42 **Abstract**

43 Nearly a decade ago, the Society for Vascular Surgery (SVS)'s wound, ischemia, and foot
44 Infection (WIFI) classification was first developed to help assess overall limb threat. However,
45 managing conditions such as diabetic foot ulcer and chronic limb-threatening ischemia can be
46 complex. For instance, certain investigative findings might initially be pending such as the level
47 of ischemia or extent of infection before the final classification is established. In addition, wounds
48 evolve rapidly, and the current classification does not allow for tracking their progression over
49 time during treatment. Therefore, we propose a supplemental consistent notation for scoring Wifi
50 re-assessment during treatment of a threatened limb inspired by the cancer staging before and after
51 neoadjuvant treatment classification system. Thus, we describe the re-scoring system and how to
52 use it. This addition to the Wifi scoring system is supported by five clinical cases of lower
53 extremity wounds. Our suggestion supports a coherent method to longitudinally communicate
54 characteristics of a threatened limb. This has potential to support high quality interdisciplinary,
55 patient-centered care and enhance the use of this classification in research. Further work is required
56 to validate this modification of a common language of risk.

57

58 **Keywords:** Diabetes, Foot Ulcer; Wound Healing Peripheral Vascular Disease; Ischemia;
59 Classification; Amputation

60

61 Diabetes-related foot complications such as diabetic foot ulcers (DFUs), peripheral arterial disease
62 including critical limb-threatening ischemia (CLTI), Charcot neuro-arthropathy and lower
63 extremity amputations (LEAs) are a leading cause of global morbidity, mortality, reduced quality
64 of life and direct and indirect healthcare costs.¹⁻³ Indeed, 5-year mortality rates associated with
65 these complications are greater compared to many cancers.⁴ Limb complications of diabetes
66 increase in people with multimorbidity such as concomitant nephropathy and cardiovascular
67 disease.⁴⁻⁶ People with an history of DFUs are at increased risk of ulcer recurrence.¹ In fact, 40%
68 of those people will develop DFU recurrence within a year, 65% within 5 years, and greater than
69 90% within 10 years.^{1,7} Because the epidemiology of diabetes-related foot complications is
70 comparable to that of cancer, and recurrence is common, after the initial healing of an index DFU,
71 it is appropriate to refer to a person not as cured of DFU, but rather as being in "DFU remission".⁸
72 In addition, as with cancer, the complexities associated with management require a comprehensive
73 and organized team approach, including the patient, their family and caregivers, to achieve the best
74 outcomes and high quality patient-centered care.⁹⁻¹²

75

76 Nearly a decade ago, Mills, Conte, Armstrong and coworkers, in concert with the Society for
77 Vascular Surgery (SVS) proposed an integrated lower extremity wound classification system
78 related to LEA risk and revascularization benefit.¹³ Inspired by cancer research, it is intended to
79 define the disease burden, analogous to the tumor, node, metastasis (TNM) system for cancer
80 staging.^{13,14} Wifl consists of a graded scoring system for wound, ischemia, and foot infection. For
81 any given threatened limb, a severity grade of 0 to 3 (i.e., none, mild, moderate, severe) is assigned
82 to grade the severity and extent of wound, ischemia, and foot infection, respectively (Figure 1).
83 On the basis of these three scores, patients are further assigned to four threatened limb clinical

84 stages corresponding to estimated risk of LEA derived by an expert panel consensus. The
85 underlying premise of Wifl is that the risk of LEA increases as the presenting disease burden
86 progresses from clinical stage 1 (very low risk) to stage 4 (high risk).¹³ However, managing the
87 threatened limb can be complex, and the impact of conservative, surgical, and medical
88 interventions on the stabilization of DFUs is not reflected in the scoring system. Additionally,
89 certain investigative findings might initially be pending such as the level of ischemia or extent of
90 infection before the final classification is established. DFUs evolve rapidly, and the current
91 classification does not allow for tracking limb progression over time during treatment and related
92 to potential recurrence of the index DFU. Moreover, these limitations create a logistical challenge
93 for utilizing Wifl for large scale reporting including in cohort studies and clinical trials. Therefore,
94 consistency in notation is required for widespread application.

95

96 Figure 1

97

98 To continue the analogy of DFU with cancer staging, a recent publication suggested an updated
99 classification to better reflect the situation after neoadjuvant therapies and to highlight the
100 differences between clinical and pathological states.¹⁵ Given similar issues in categorizing DFUs
101 post treatment such as revascularization and limb salvage, treatment of osteomyelitis or
102 debridement or minor amputation, with a supplemental Wifl notation is appropriate and would
103 assist the clinician as well as provide a consistent approach for use in clinical studies. A recent
104 study demonstrated that Wifl restaging is an important tool for predicting limb loss and assessing
105 adequacy of intervention, more so than baseline Wifl alone.¹⁶ Therefore, the aim of this

106 communication is to propose a revised, consistent notation for scoring Wifl re-assessment during
107 treatment of a threatened limb for the clinical and research community with the intention to make
108 it practical to use on a daily basis. Thus, we describe the re-scoring system.

109

110 **Notation for re-scoring Wifl**

111 In order to address the issue of either upgrading or downgrading the Wifl score of a threatened
112 limb, and to reflect the actual condition, and to allow the latitude of a pending score, identifying
113 the timeline to the event and associated interventions is important. Thus, it will be possible to
114 classify a DFU for example, according to the stage of management: before treatment, during/after
115 treatment and at remission. This is separated in four phases: primary presentation (p), during
116 therapy (y), healed (h) or recurrent (r).

117

118 When there is missing data to complete the final Wifl score, for example, when the clinician is
119 awaiting the results of a pending vascular investigation to identify the ischemia status, or awaiting
120 the results of histology/laboratory data to support the presence of bone involvement in infection,
121 the number is temporarily replaced by the hashtag (#) until the score can be completed with
122 certainty. In this case, it is still necessary to identify the index phase (Figure 2).

123

124 Figure 2

125

126 Thus, for an index ulcer, the assessor (i.e., clinician or researcher) should always establish a score
127 for the primary presentation that is associated with the risk of major LEA and/or the benefits of
128 revascularization as a preliminary Wifl score or “pWifl” score. During and following the

129 treatment, whatever the nature and number of treatments and the length of follow up, the scorer
130 can define the classification as many times as needed by using a post treatment WIfI score or
131 “tWIfI” score. Considering that the goal is to stabilize (or to maintain in remission) the threatened
132 limb condition, it is relevant to repeat the score when the condition is deemed healed (h). The
133 repeated score is still relevant as there could still be an ischemic component to follow. Therefore,
134 the user should note the status using “hWIfI”.

135

136 A threatened limb, or healed limb is often evolving gradually, changing rapidly and is at high-risk
137 of recurrence. Indeed, the healed WIfI score is not a static measurement and that it is in fact a cycle
138 This cycle can then be restarted using the notation and this is based on the adapted clinical
139 algorithm suggested by Conte and al. (2020) to implement limb staging with the WIfI as a part of
140 the initial assessment of CLTI (Figure 3).¹⁷ On the other hand, the possibility that the cycle stops
141 after the healing score is plausible. This indicates that the team has accomplished its mission to
142 maximize ulcer-free, hospital-free, and activity-rich days, the same way a cancer survivor is
143 deemed to maximize cancer-free days.^{4,18} Alternatively, if limb salvage is not attained and limb
144 loss ensues, then this is designated with a capital R to indicate limb loss due to an index ulcer as
145 “RWIfI” This is a comprehensive re-notation that can be preconize in research context.

146

147 Figure 3

148

149 **Definitions**

150 *Primary presentation (p)*

151 This is the first WifI score that is assigned when the diagnosis of the limb-threatening condition
152 such DFU and CLTI. This score is made according to clinical criteria established by former
153 guidelines. The pending score should be completed before proceeding to the next phase
154 considering that it is the score that determines the LEA risk and revascularization risk according
155 to the initial WifI.¹³ This represents the initial state without treatment. This should be evaluated
156 by a trained and competent health care provider that can diagnose the components of wound,
157 ischaemia and infection within their scope of practice.

158

159 *During treatment/therapy (t)*

160 For our purpose, therapies, treatments, and cares are synonym to attempted remediation of the
161 limb-threatening condition following the diagnosis. There are a multitude of treatments for the
162 conditions that can supplement the WifI score. Therefore, any action or way of treating a patient
163 or a condition medically or surgically such as management and care to prevent, cure, ameliorate,
164 or slow progression of a threatened limb condition is included in this phase. These treatments must
165 be supported by the suitable guidelines and respect the ethical principles of research with human
166 subjects. This score can be use in the initial treatment strategy using the holistic patient, limb,
167 anatomy (PLAN) framework or during the clinical reassessment and can be re-scored according
168 to the clinical reassessment as needed.

169

170 *Healed (or controlled or stable) (h)*

171 Food and Drug Administration (FDA) defines healing as the 100% re-epithelialization of the
172 wound surface with no discernable exudate and without drainage or dressing, confirmed at two
173 visits two weeks apart.¹⁹ Moreover, a blinded adjudication for wound assessment is suggested in

174 the case of a clinical trial.²⁰ As discussed above, a DFU would be in remission instead of healed.
175 The International working group on Diabetic Foot (IWGDF) defines it as an intact skin and
176 absence of infection of the complete foot after healing of any DFUs.²¹ Thus, the final score
177 associated with this phase should be established according to the above conditions, confirmed at
178 two week intervals by a final blinded wound assessment.²²

179

180 *Recurrence (r)*

181 The IWGDF defines DFU recurrence as a new foot ulcer in a person who has a history of DFU,
182 irrespective of location and time, since previous DFU.²¹ Nevertheless, with this notation, the
183 recurrences are counted only if it is the same indexed DFU/wounds. If it is a new wound location,
184 it is not a recurrence. This is supporting the complexity of the lower limb vascularization related
185 to the healing potential and Wifl score.²³ For a new wound, it is then necessary to established the
186 score based on the primary presentation notation.

187

188 *Limb loss (R)*

189 Limb loss is any major amputation defined as any resection proximal to the ankle.²¹

190

191 **Strengths and Limitation**

192 This consistent notation for re-scoring tissue loss, level of ischemia, and severity of foot infection
193 assessment during treatment aims to meet the needs of both the clinical and scientific community
194 to enhance person-centered care and inform better practices. Moreover, it has the potential to
195 promote better understanding, communication, and follow-up within the team but also in broader
196 dissemination In addition, it facilitates the use of the Wifl classification in a general way as we

197 have established clear definitions for each phase according to the stage of clinical management.
198 This addition does not distort the original SVS classification but can supplement the use of WIfI
199 as needed. In the same way, it allows longitudinal evaluation of the person with wounds in relation
200 with treatments (i.e., before and after) including the number of recurrences if necessary. This
201 notation is flexible considering the use of a specific notation (#) while waiting for new data from
202 investigations as an example. The "pending" result was previously ambiguous. As the initial WIfI
203 score was intended to assess 1-year major amputation risk or benefit of revascularization, our
204 suggestion evaluates progression rather than assessing risk or benefit. Thus, these predictive values
205 can be considered only when assessing the WIfI score of the primary presentation (p) or at the
206 initial assessment for a recurrence (r). Considering the variability of treatment options and the
207 great heterogeneity in terms of dose, exposure, time, number, follow up, etc., attributable to this
208 stage of management, a general predictive value seems unrealistic. However, it can open the way
209 to evaluate predictive values of a specific care pathway or treatments, and this 2.0 WIfI notation
210 can accompany efforts in this direction. Lastly, the revised scoring system we have suggested
211 requires validation and evaluation for repeatability, which we plan to undertake. It is consistent
212 with previous work implementing global guidelines for CLTI in clinical practice.²⁴

213

214 **Conclusion**

215 Our suggestion supports a coherent way to longitudinally communicate characteristics of a
216 threatened limb. This has potential to support high quality interdisciplinary patient-centered care.
217 This is one more improved way in the “toolbox” of clinicians and researchers to maximize ulcer-
218 free, hospitalization-free, activity-rich days for people with limb-threatening conditions, in the

219 same way the team and cancer survivors strive to maximize cancer-free days. We look forward to
220 further efforts to validate this modification of a common language of risk.

221

222 **References**

- 223 1. Armstrong DG, Boulton AJ, Bus SA. Diabetic foot ulcers and their recurrence. *New*
224 *England Journal of Medicine*. 2017;376(24):2367-2375.
- 225 2. Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJ. Current challenges
226 and opportunities in the prevention and management of diabetic foot ulcers. *Diabetes care*.
227 2018;41(4):645-652.
- 228 3. Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. *Journal of*
229 *Clinical Orthopaedics and Trauma*. 2021;17:88-93.
- 230 4. Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five
231 year mortality and direct costs of care for people with diabetic foot complications are comparable
232 to cancer. *Journal of foot and ankle research*. 2020;13(1):1-4.
- 233 5. Thorud JC, Plemmons B, Buckley CJ, Shibuya N, Jupiter DC. Mortality after
234 nontraumatic major amputation among patients with diabetes and peripheral vascular disease: a
235 systematic review. *the journal of foot and ankle surgery*. 2016;55(3):591-599.
- 236 6. Fard B, Dijkstra PU, Voesten HG, Geertzen JH, Group NS. Mortality, reamputation, and
237 preoperative comorbidities in patients undergoing dysvascular lower limb amputation. *Annals of*
238 *vascular surgery*. 2020;64:228-238.
- 239 7. Huang ZH, Li SQ, Kou Y, Huang L, Yu T, Hu A. Risk factors for the recurrence of
240 diabetic foot ulcers among diabetic patients: a meta-analysis. *International wound journal*.
241 2019;16(6):1373-1382.

- 242 8. Armstrong DG, Mills JL. Toward a change in syntax in diabetic foot care: prevention
243 equals remission. *Journal of the American Podiatric Medical Association*. 2013;103(2):161-162.
- 244 9. Blanchette V, Brousseau-Foley M, Cloutier L. Effect of contact with podiatry in a team
245 approach context on diabetic foot ulcer and lower extremity amputation: systematic review and
246 meta-analysis. *Journal of foot and ankle research*. 2020;13(1):1-12.
- 247 10. Musuuza J, Sutherland BL, Kurter S, Balasubramanian P, Bartels CM, Brennan MB. A
248 systematic review of multidisciplinary teams to reduce major amputations for patients with
249 diabetic foot ulcers. *Journal of vascular surgery*. 2019;
- 250 11. Bernatchez J, Mayo A, Kayssi A. The epidemiology of lower extremity amputations,
251 strategies for amputation prevention, and the importance of patient-centered care. Elsevier;
252 2021:54-58.
- 253 12. Khan T, Shin L, Woelfel S, Rowe V, Wilson BL, Armstrong DG. Building a scalable
254 diabetic limb preservation program: four steps to success. *Diabetic foot & ankle*.
255 2018;9(1):1452513.
- 256 13. Mills Sr JL, Conte MS, Armstrong DG, et al. The society for vascular surgery lower
257 extremity threatened limb classification system: risk stratification based on wound, ischemia, and
258 foot infection (WIFI). *Journal of vascular surgery*. 2014;59(1):220-234. e2.
- 259 14. Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP. *AJCC cancer staging atlas*.
260 Springer; 2006.
- 261 15. Byrd DR, Brierley JD, Baker TP, Sullivan DC, Gress DM. Current and future cancer
262 staging after neoadjuvant treatment for solid tumors. *CA: A Cancer Journal for Clinicians*.
263 2021;71(2):140-148.


- 264 16. Leithead C, Spangler E, Passman M, et al. Importance of Postprocedural Wound,
265 Ischemia, and Foot Infection Restaging in Predicting Limb Salvage. *Journal of Vascular*
266 *Surgery*. 2017;65(1):e7-e8.
- 267 17. Mills JL. An Integrated Approach for the Effective Management of Limb-Threatening
268 Ischaemia in the Diabetic Foot. *The Diabetic Foot Syndrome*. Karger Publishers; 2018:147-160.
- 269 18. Khan T, Armstrong DG. Ulcer-free, hospital-free and activity-rich days: three key
270 metrics for the diabetic foot in remission. MA Healthcare London; 2018. p. S3-S4.
- 271 19. Groupa FWHCF. Guidance for industry: Chronic cutaneous ulcer and burn wounds—
272 developing products for treatment: DRAFT—NOT FOR IMPLEMENTATION. *Wound Repair*
273 *and Regeneration*. 2001;9(4):258-268.
- 274 20. Gould L, Li WW. Defining complete wound closure: closing the gap in clinical trials and
275 practice. *Wound Repair and Regeneration*. 2019;27(3):201-224.
- 276 21. van Netten JJ, Bus SA, Apelqvist J, et al. Definitions and criteria for diabetic foot
277 disease. *Diabetes/metabolism research and reviews*. 2020;36:e3268.
- 278 22. Association WM. World Medical Association Declaration of Helsinki. Ethical principles
279 for medical research involving human subjects. *Bulletin of the World Health Organization*.
280 2001;79(4):373.
- 281 23. Weaver ML, Hicks CW, Canner JK, et al. The Society for Vascular Surgery Wound,
282 Ischemia, and foot Infection (WIFI) classification system predicts wound healing better than
283 direct angiosome perfusion in diabetic foot wounds. *Journal of vascular surgery*.
284 2018;68(5):1473-1481.
- 285 24. Conte MS, Mills JL, Bradbury AW, White JV. Implementing global chronic limb-
286 threatening ischemia guidelines in clinical practice: Utility of the Society for Vascular Surgery

287 Threatened Limb Classification System (WIFI). *Journal of Vascular Surgery*. 2020;72(4):1451-
288 1452.

289 25. Armstrong DG, Mills JL. Juggling risk to reduce amputations: the three-ring circus of
290 infection, ischemia and tissue loss-dominant conditions. *Wound Medicine*. 2013;1:13-14.

291

292



293


294 Figure 1 SWS Wifl classification system, adapted from Armstrong & Mills (2013) ²⁵

295

296

297

298




299

300 Figure 2 Schematization of the supplemental WIfI notation

301

302



303

304

305 Figure 2 Continuous evaluation and re-staging. Adapted clinical algorithm from Conte and al.

306 2020²⁴

307 Abbreviation: WIFI: Wounds, Ischemia and foot Infection Classification; CLTI: Chronic Limb-

308 Threatening Ischemia; DFU: Diabetic Foot Ulcer.

309